Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04204837
Other study ID # CA209-587
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date March 6, 2017
Est. completion date December 2027

Study information

Verified date April 2024
Source Salzburger Landeskliniken
Contact Martin Laimer, MD
Phone +4357255
Email m.laimer@salk.at
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab (Group 1) and Nivolumab plus Relatlimab (Group 2) in patients with locally advanced/metastatic squamous cell carcinoma of the skin using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment (Time Frame Group 2: From first dose up to 5 years)


Recruitment information / eligibility

Status Recruiting
Enrollment 61
Est. completion date December 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Men and women, 18 years of age and older on day of signing written informed consent 2. Histologically or cytologically documented locally-advanced and/or metastatic squamous cell carcinoma of the skin (stage III/IV AJCC 2010) that is incurable 3. Archival tumor tissue available for evaluation of PD-L1 and LAG-3 expression 4. Measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) 5. Life expectancy of at least 12 weeks 6. Eastern Cooperative Oncology Group (ECOG) Performance status of 0-2 7. Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to registration: - WBC = 2000/µl - Neutrophils = 1500/µL - Platelets = 100 x103/µL - Hemoglobin > 9.0 g/dL - Serum creatinine = 1.5 x ULN or creatinine clearance (CrCl) = 40 mL/min (if using the Cockcroft-Gault formula below): Female CrCl = (140 - age in years) x weight in kg x 0.85/72 x serum creatinine in mg/dL Male CrCl = (140- age in years) x weight in kg x 1.00/72 x serum creatinine in mg/dL - AST/ALT = 3 x ULN - Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL) - Negative pregnancy test and effective contraception (Pearl-Index <1) for for women of childbearing potential (WOCBP) if the risk of conception exists 8. Prior radiotherapy must have been completed at least 2 weeks prior to study drug administration 9. Prior systemic antibiotic treatment must have been completed at least 30 days prior to stool sample collection Exclusion Criteria: 1. Patient is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment 2. Prior therapy with CTLA-4, PD-1 or LAG-3 antibodies 3. History of myocarditis, regardless of etiology 4. Troponin T (TnT) or I (TnI) > 2× institutional upper limit of normal (ULN). Participants with TnT or TnI levels between > 1× to 2× ULN will be permitted if repeat levels within 24 hours are = 1× ULN. If TnT or TnI levels are between > 1× to 2× ULN within 24 hours, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator. When repeat levels within 24 hours are not available, a repeat test should be conducted as soon as possible. If TnT or TnI repeat levels beyond 24 hours are < 2× ULN, the participant may undergo a cardiac evaluation and be considered for treatment, based on a favorable benefit/risk assessment by the Investigator 5. A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease 6. Known active central nervous system (CNS) metastases and/or carcinomatous meningitis 7. Known additional malignancy that is progressing or requires active treatment. Patients with chronic lymphocytic leukemia that is stable under active therapy are eligible for inclusion. 8. An active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger 9. Patients with serious intercurrent illness, requiring hospitalization 10. Other serious illnesses, e.g. serious infections requiring antibiotics 11. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial 12. Pregnancy (absence to be confirmed by ß-HCG urinary test, minimum sensitivity 25 IU/L or equivalent units of HCG)) or lactation period 13. Women of childbearing potential (WOCBP): Refusal or inability to use effective means of contraception (Pearl-Index <1) 14. History of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) 15. Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection 16. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator 17. Known hypersensitivity reaction to any of the components of study treatment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nivolumab
Nivolumab will be given on Day 1 of every 14-day cycle (Q2W) at a dose of 240 mg as an IV infusion until progression, unacceptable toxicity or discontinuation for other reasons for up to 2 years.
Nivolumab plus Relatlimab
Patients wil receive a fixed-dose combination of nivolumab 480 mg and relatlimab 160 mg by intravenous infusion every four weeks (Q4W) (Group 2) for up to two years after initial dosing or until PD - or absence of investigator-assessed clinical benefit

Locations

Country Name City State
Austria Universitätsklinikum Graz - LKH, Klinische Abteilung für Onkologie Graz
Austria LKH Innsbruck Universitätsklinik für Dermatologie und Venerologie Innsbruck
Austria Klinikum Klagenfurt am Wörthersee Klagenfurt
Austria Universitätsklinik für Dermatologie und Allergologie der Paracelsus medizinischen Privatuniversität Salzburg Salzburg
Austria Abteilung für Haut- und Geschlechtskrankheiten, Universitätsklinikum St. Pölten Karl Landsteiner Privatuniversität für Gesundheitswissenschaften St.Pölten
Austria Med Uni Wien, Univ. Klinik für Dermatologie Vienna
Austria Klinikum Wels-Grieskirchen GmbH Wels

Sponsors (2)

Lead Sponsor Collaborator
Salzburger Landeskliniken Bristol-Myers Squibb

Country where clinical trial is conducted

Austria, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Response Rate (ORR) using Response Criteria in Solid Tumors Version 1.1 (RECIST1.1) per site assessment up to 5 years
Secondary Disease Control Rate (DCR) Disease Control Rate (DCR) using Response Criteria in Solid Tumors version 1.1 (RECIST1.1) per site assessment up to 5 years
Secondary Duration of Response (DOR) in patients who achieve partial response (PR) or better up to 5 years
Secondary Progression Free Survival (PFS) up to 5 years
Secondary Overall Survival (OS) up to 5 years
Secondary ORR and DCR for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells up to 5 years
Secondary Number and severity of adverse events up to 5 years
Secondary DOR, PFS and OS for patients with PD-L1-positive tumor expression and/or positive LAG-3 expression of tumor-infiltrating cells up to 5 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03291002 - Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC Phase 1
Active, not recruiting NCT06327971 - Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology
Not yet recruiting NCT03621462 - Elucid Labs AIDA™ - Labelled Image Acquisition Protocol N/A
Not yet recruiting NCT04480645 - CivaDerm(TM) Surface Therapy Pilot Study Early Phase 1
Recruiting NCT03370861 - How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
Recruiting NCT06014086 - Intratumoral PH-762 for Cutaneous Carcinoma Phase 1
Completed NCT02347813 - Preventing Squamous Cell Skin Cancer Phase 2
Terminated NCT01984892 - Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Phase 2
Completed NCT00563290 - Dasatinib in Treating Patients With Unresectable or Metastatic Squamous Cell Skin Cancer or RAI Stage 0-I Chronic Lymphocytic Leukemia Phase 2
Completed NCT03894618 - SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas Phase 1
Terminated NCT01823679 - Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin Phase 2
Completed NCT00126555 - Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Phase 2
Completed NCT00089180 - T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant Phase 2
Not yet recruiting NCT05246228 - Immune System Modulation and Outcome in High-risk cSCC Treated With Surgery and Radiotherapy
Recruiting NCT05886140 - Carrilizumab Combined With White Purple for Squamous Cell Carcinoma of Skin N/A
Completed NCT02324608 - Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer N/A
Recruiting NCT02717936 - Investigation of Desmoplastic Squamous Cell Carcinoma N/A
Recruiting NCT05482880 - Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region
Withdrawn NCT01465815 - Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN) Phase 1/Phase 2
Recruiting NCT05490485 - Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma Phase 2